Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ARTELO BIOSCIENCES, INC.

Get SEC filing alerts via email and in your feed for ARTELO BIOSCIENCES, INC.

ARTL ARTLW ATLEW

ARTELO BIOSCIENCES, INC.

About ARTELO BIOSCIENCES, INC.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company based in California, focused on developing therapeutics that modulate lipid-signaling pathways, particularly the endocannabinoid system. Its key products include ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. With significant market opportunities exceeding $2 billion for cancer anorexia and over $1 billion for neuropathy, Artelo is advancing innovative therapies through clinical trials and strategic partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ARTELO BIOSCIENCES, INC.

1
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports Increased Net Loss and Improved Financial Position in Latest 10-Q Filing

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports $12.9 Million Net Loss and Decreased Cash Reserves for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports $8.7 Million Net Loss and Working Capital Deficit

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports Increased Net Loss and Deteriorating Financial Position for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports $2.4 Million Net Loss in Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports $9.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ARTELO BIOSCIENCES, INC. Artelo Biosciences Reports Q3 Financial Results, Improved Liquidity, and Reduced Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments